Amit Roy

University at Buffalo, SUNY

H指数:31

被引数:3,811

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Scoping review of the role of pharmacometrics in model-informed drug development

基于模型的新药研发中药物动力学的作用范围综述

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

IF2.8

2025-10-150

OAAI

Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation

皮下纳武利尤单抗的模型引导药物研发：通过临床试验模拟比较药代动力学分析方法学

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-09-010

OAAI

Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors

Repotrectinib暴露-反应分析，以支持ROS1阳性NSCLC或NTRK阳性实体瘤患者的剂量推荐

cpt pharmacometrics systems pharmacology

IF0

2025-08-170

OAAI

A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

一种新的经验性自诱导模型，用于表征携带ALK、ROS1或NTRK1-3重排的成年人和青少年晚期实体瘤患者的群体药代动力学，并推荐Repotrectinib的剂量

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-05-010

OAAI

Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab

基于模型的尼鲁单抗单药治疗及联合伊匹单抗的免疫原性评估

AAPS JOURNAL

IF3.7

2025-04-250

PRE

Developing an evaluation strategy in Kashmir: assessing the impact of an arts intervention with school children in an area of conflict

PERSPECTIVES IN PUBLIC HEALTH

IF2.6

2024-11-060

PRE

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-08-131

OAAI

Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-07-250

OAAI

Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-05-024

OAAI

Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-01-287

OAAI

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-01-080

Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-12-183

PRE

Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-11-061

Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2023-05-308

Microgravity: New aspect for breast cancer treatment, a review

ACTA ASTRONAUTICA

IF3.4

2022-01-016

PRE

Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-06-114

OAAI

Cytoprotective Effects of Cerium and Selenium Nanoparticles on Heat-Shocked Human Dermal Fibroblasts: An in vitro Evaluation (vol 11, pg 1427, 2016)

INTERNATIONAL JOURNAL OF NANOMEDICINE

IF6.5

2021-06-010

OAAI

Industrial Perspective on the Benefits Realized from the FDA's Model-Informed Drug Development Paired Meeting Pilot Program

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-05-1516

OAAI

Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

CANCER RESEARCH

IF16.6

2020-08-151

PRE

A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-12-1925

PREAI

Amit Roy

个人简介

教育背景

工作经历

荣誉奖项

研究方向